Monogram | GenomeWeb

Monogram

With an ever-increasing number of options for diagnostic sequencing, the decision of whether to do a gene panel, exome, or whole genome becomes complicated.

When inking companion diagnostic deals with drug developers, most test makers are trying to get beyond fee-for-service arrangements and strike more creative agreements with potential for bigger profits over a longer period of time.

Quest Diagnostics has published a validation study of its laboratory-developed HIV tropism test that uses a combination of Sanger sequencing and next-generation sequencing on Roche's 454 GS Junior platform.

Siemens Inks New Companion Dx Collaborations with ViiV Healthcare, Tocagen

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

Using a systems biology approach, researchers from Switzerland and the US have identified epistatic interactions involving mutations in two HIV-1 enzymes that can help predict the virus' ability to replicate in the presence or absence of more than a dozen drugs.

Pairings

Premium

William Welch, Dean Schorno, Samuel Broder, Mark Velleca, Paul Beresford, Leroy Hood

Lab21 will offer the service from its UK operations "with immediate effect," and eventually plans to offer the test as part of its comprehensive HIV service at its US facility in Greenville, SC.

For Dx shops developing pharmacogenomic tests without big pharma's help, Medco says it can offer a better value proposition when it comes to driving adoption and reimbursement for their tests.

Although the collaboration is aimed at increasing physician knowledge of genomic testing associated with all HIV drugs, it appears to have stemmed from lower-than-expected sales of Pfizer's CCR5-antagonist Selzentry.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.